Notably, we demonstrated that the combination of PUMA knockdown and C75, an early clinical FASN inhibitor [58], enhanced the inhibitory effect on ccRCC growth compared to individual treatments, in both in vitro and in vivo experiments. This evidence concerns the gene FASN and nonpapillary renal cell carcinoma.